Efficacy and safety of surufatinib in the treatment of patients with neuroendocrine tumor: a real-world study in Chinese population.
Efficacy
GEP-NETs
Primary tumor site
Surufatinib
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
31 Oct 2024
31 Oct 2024
Historique:
received:
09
04
2024
accepted:
23
10
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
epublish
Résumé
Neuroendocrine tumors (NETs) are rare neoplasms that originate from peptidergic neurons and neuroendocrine cells. Due to their increasing incidence, effective treatment strategies are required. Surufatinib, a novel small-molecule inhibitor with antiangiogenic and immunomodulatory effects, has shown promise in clinical trials for advanced NETs. However, the efficacy and safety of surufatinib are influenced by multiple factors, and there is currently a lack of sufficient real-world studies to explore these potential influencing factors. We conducted a retrospective study on 133 patients with NETs who were treated with surufatinib at Sun Yat-sen University Cancer Center. Patients were histologically confirmed to have primary NETs. Statistical analyses, including Cox regression models and Kaplan-Meier curves, were conducted to assess the impact of the primary tumor site on progression-free survival (PFS) and overall survival (OS). Patients with gastroenteropancreatic NETs (GEP-NETs) exhibited significantly longer PFS and OS compared to extraGEP-NETs patients. Subgroup analyses also revealed variations in survival outcomes among patients with liver metastases depending on the primary tumor site. Adverse events (AEs), including proteinuria and increased bilirubin, were more common in GEP-NETs patients. These findings emphasize the importance of considering primary tumor site in treatment decisions for NETs. Primary tumor site is a critical factor influencing the efficacy of surufatinib in NETs. Clinicians should consider this factor when determining treatment strategies.
Sections du résumé
BACKGROUND
BACKGROUND
Neuroendocrine tumors (NETs) are rare neoplasms that originate from peptidergic neurons and neuroendocrine cells. Due to their increasing incidence, effective treatment strategies are required. Surufatinib, a novel small-molecule inhibitor with antiangiogenic and immunomodulatory effects, has shown promise in clinical trials for advanced NETs. However, the efficacy and safety of surufatinib are influenced by multiple factors, and there is currently a lack of sufficient real-world studies to explore these potential influencing factors.
METHODS
METHODS
We conducted a retrospective study on 133 patients with NETs who were treated with surufatinib at Sun Yat-sen University Cancer Center. Patients were histologically confirmed to have primary NETs. Statistical analyses, including Cox regression models and Kaplan-Meier curves, were conducted to assess the impact of the primary tumor site on progression-free survival (PFS) and overall survival (OS).
RESULTS
RESULTS
Patients with gastroenteropancreatic NETs (GEP-NETs) exhibited significantly longer PFS and OS compared to extraGEP-NETs patients. Subgroup analyses also revealed variations in survival outcomes among patients with liver metastases depending on the primary tumor site. Adverse events (AEs), including proteinuria and increased bilirubin, were more common in GEP-NETs patients. These findings emphasize the importance of considering primary tumor site in treatment decisions for NETs.
CONCLUSIONS
CONCLUSIONS
Primary tumor site is a critical factor influencing the efficacy of surufatinib in NETs. Clinicians should consider this factor when determining treatment strategies.
Identifiants
pubmed: 39482595
doi: 10.1186/s12885-024-13089-6
pii: 10.1186/s12885-024-13089-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1342Subventions
Organisme : Natural Science Foundation of Guangdong Province
ID : 2023A1515010713
Informations de copyright
© 2024. The Author(s).
Références
Di Domenico A, Wiedmer T, Marinoni I, Perren A. Genetic and epigenetic drivers of neuroendocrine tumours (NET). Endocr Relat Cancer. 2017;24(9):R315–34.
doi: 10.1530/ERC-17-0012
pubmed: 28710117
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.
doi: 10.1001/jamaoncol.2017.0589
pubmed: 28448665
pmcid: 5824320
Pozas J, Alonso-Gordoa T, Román MS, Santoni M, Thirlwell C, Grande E, et al. Novel therapeutic approaches in GEP-NETs based on genetic and epigenetic alterations. Biochim Biophys Acta Rev Cancer. 2022;1877(5):188804.
doi: 10.1016/j.bbcan.2022.188804
pubmed: 36152904
Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017;19(12):991–1002.
doi: 10.1016/j.neo.2017.09.002
pubmed: 29091800
pmcid: 5678742
Xu J. Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs). Ther Adv Med Oncol. 2021;13:17588359211042689.
doi: 10.1177/17588359211042689
pubmed: 34484432
pmcid: 8411625
Ichikawa Y, Kobayashi N, Takano S, Kato I, Endo K, Inoue T. Neuroendocrine tumor theranostics. Cancer Sci. 2022;113(6):1930–8.
doi: 10.1111/cas.15327
pubmed: 35271754
pmcid: 9207370
Walter MA, Nesti C, Spanjol M, Kollár A, Bütikofer L, Gloy VL, et al. Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis. Cochrane Database Syst Rev. 2021;11(11):Cd013700.
pubmed: 34822169
Xu J, Shen L, Bai C, Wang W, Li J, Yu X, et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(11):1489–99.
doi: 10.1016/S1470-2045(20)30493-9
pubmed: 32966810
Zhang J, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer. 2007;109(8):1478–86.
doi: 10.1002/cncr.22554
pubmed: 17340592
Syed YY, Surufatinib. First Approval Drugs. 2021;81(6):727–32.
pubmed: 33788183
Zhang P, Shi S, Xu J, Chen Z, Song L, Zhang X, et al. Surufatinib plus Toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: an open-label, single-arm, multi-cohort phase II trial. Eur J Cancer. 2024;199:113539.
doi: 10.1016/j.ejca.2024.113539
pubmed: 38237373
Koumarianou A, Kaltsas G. Surufatinib - a novel oral agent for neuroendocrine tumours. Nat Rev Endocrinol. 2021;17(1):9–10.
doi: 10.1038/s41574-020-00439-0
pubmed: 33128026
Xu J, Shen L, Zhou Z, Li J, Bai C, Chi Y, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(11):1500–12.
doi: 10.1016/S1470-2045(20)30496-4
pubmed: 32966811
Kaderli RM, Spanjol M, Kollár A, Bütikofer L, Gloy V, Dumont RA, et al. Therapeutic options for neuroendocrine tumors: a systematic review and network Meta-analysis. JAMA Oncol. 2019;5(4):480–9.
doi: 10.1001/jamaoncol.2018.6720
pubmed: 30763436
pmcid: 6459123
Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2018;68(6):471–87.
doi: 10.3322/caac.21493
pubmed: 30295930
Cai L, Michelakos T, Deshpande V, Arora KS, Yamada T, Ting DT, et al. Role of Tumor-Associated macrophages in the clinical course of pancreatic neuroendocrine tumors (PanNETs). Clin Cancer Res. 2019;25(8):2644–55.
doi: 10.1158/1078-0432.CCR-18-1401
pubmed: 30670493
pmcid: 6582654
Li J, Cheng Y, Bai C, Xu J, Shen L, Li J, et al. Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies. ESMO Open. 2022;7(2):100453.
doi: 10.1016/j.esmoop.2022.100453
pubmed: 35344750
pmcid: 9058866
Zhang J, Zhu H, Shen L, Li J, Zhang X, Bai C, et al. Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib. Chin J Cancer Res. 2023;35(5):526–35.
doi: 10.21147/j.issn.1000-9604.2023.05.09
pubmed: 37969958
pmcid: 10643338
Tierney JF, Poirier J, Chivukula S, Pappas SG, Hertl M, Schadde E, et al. Primary Tumor Site affects survival in patients with gastroenteropancreatic and neuroendocrine liver metastases. Int J Endocrinol. 2019;2019:9871319.
doi: 10.1155/2019/9871319
pubmed: 30992703
pmcid: 6434277
Russolillo N, Vigano L, Razzore P, Langella S, Motta M, Bertuzzo F, et al. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: comparison of gastro-enteric and pancreatic locations. Eur J Surg Oncol. 2015;41(6):751–7.
doi: 10.1016/j.ejso.2015.02.011
pubmed: 25887286
Das S, Dasari A, Epidemiology. Incidence, and prevalence of neuroendocrine neoplasms: are there global differences? Curr Oncol Rep. 2021;23(4):43.
doi: 10.1007/s11912-021-01029-7
pubmed: 33719003
pmcid: 8118193
Hallet J, Law C, Singh S, Mahar A, Myrehaug S, Zuk V, et al. Risk of Cancer-Specific death for patients diagnosed with neuroendocrine tumors: a Population-based analysis. J Natl Compr Canc Netw. 2021;19(8):935–44.
doi: 10.6004/jnccn.2020.7666
pubmed: 34087785
Nøst TH, Alcala K, Urbarova I, Byrne KS, Guida F, Sandanger TM, et al. Systemic inflammation markers and cancer incidence in the UK Biobank. Eur J Epidemiol. 2021;36(8):841–8.
doi: 10.1007/s10654-021-00752-6
pubmed: 34036468
pmcid: 8416852
Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176–81.
doi: 10.1016/j.lungcan.2017.07.024
pubmed: 28838390
Zhang L, Ma W, Qiu Z, Kuang T, Wang K, Hu B, et al. Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors. Front Immunol. 2023;14:1219929.
doi: 10.3389/fimmu.2023.1219929
pubmed: 37545502
pmcid: 10401046
Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212–22.
doi: 10.1158/1078-0432.CCR-14-0442
pubmed: 25271081
Ye K, Xiao M, Li Z, He K, Wang J, Zhu L, et al. Preoperative systemic inflammation response index is an independent prognostic marker for BCG immunotherapy in patients with non-muscle-invasive bladder cancer. Cancer Med. 2023;12(4):4206–17.
doi: 10.1002/cam4.5284
pubmed: 36214475
Shu XP, Xiang YC, Liu F, Cheng Y, Zhang W, Peng D. Effect of serum lactate dehydrogenase-to-albumin ratio (LAR) on the short-term outcomes and long-term prognosis of colorectal cancer after radical surgery. BMC Cancer. 2023;23(1):915.
doi: 10.1186/s12885-023-11446-5
pubmed: 37770882
pmcid: 10537469
Xu H, Lin T, Ai J, Zhang J, Zhang S, Li Y, et al. Utilizing the Lactate dehydrogenase-to-albumin ratio for Survival Prediction in patients with bladder Cancer after Radical Cystectomy. J Inflamm Res. 2023;16:1733–44.
doi: 10.2147/JIR.S384338
pubmed: 37096127
pmcid: 10122464
Xiang JX, Qian YR, He J, Lopez-Aguiar AG, Poultsides G, Rocha F, et al. Low Prognostic Nutritional Index is Common and Associated with poor outcomes following curative-intent resection for gastro-entero-pancreatic neuroendocrine tumors. Neuroendocrinology. 2024;114(2):158–69.
doi: 10.1159/000534075
pubmed: 37703840
Yang L, Fu M, Yu L, Wang H, Chen X, Sun H. Value of markers of systemic inflammation for the prediction of postoperative progression in patients with pancreatic neuroendocrine tumors. Front Endocrinol (Lausanne). 2024;15:1293842.
doi: 10.3389/fendo.2024.1293842
pubmed: 38370351
Shi M, Zhao W, Zhou F, Chen H, Tang L, Su B, et al. Neutrophil or platelet-to-lymphocyte ratios in blood are associated with poor prognosis of pulmonary large cell neuroendocrine carcinoma. Transl Lung Cancer Res. 2020;9(1):45–54.
doi: 10.21037/tlcr.2020.01.17
pubmed: 32206552
pmcid: 7082296